New England Journal of Medicine· 2020Q1

Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19

Muthiah Vaduganathan, Orly Vardeny, Thomas Michel, John J.V. McMurray et al.

2,171citations
Q1SCImago
2020year

Short summary

This study found no evidence that continuing renin–angiotensin–aldosterone system (RAAS) inhibitors increases the risk of severe Covid-19 outcomes or mortality.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Endocrinology, Diabetes and Metabolism

Endocrinology, Diabetes and MetabolismMedicine